Reparixin is primarily used in research and clinical settings for its anti-inflammatory properties, particularly as a selective inhibitor of chemokine receptors like CXCR1 and CXCR2. These receptors play a key role in neutrophil activation and migration, making Reparixin valuable in conditions involving excessive inflammatory responses. It has been investigated in the context of organ transplantation, especially in reducing ischemia-reperfusion injury. By blocking neutrophil infiltration, it helps protect tissues from inflammatory damage after blood flow is restored. Studies have explored its use in liver, lung, and pancreatic islet transplantation to improve graft survival and function. Reparixin is also being studied in autoimmune and inflammatory diseases, including type 1 diabetes, where inflammation contributes to beta-cell destruction. Its ability to modulate the immune response without broad immunosuppression makes it a promising candidate for targeted therapies. In oncology, Reparixin has shown potential in disrupting tumor microenvironment signaling, particularly in blocking cancer stem cell activity in certain breast cancers, thereby possibly reducing tumor progression and metastasis. Most applications remain in preclinical or clinical trial phases, with emphasis on harnessing its anti-inflammatory and immune-modulating effects in a controlled manner.